These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pure class III agents for prevention of sudden cardiac death. Pratt CM J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526 [TBL] [Abstract][Full Text] [Related]
5. Beta-blockers and amiodarone for the primary prevention of sudden cardiac death. Frankenberger O; Steinberg JS Curr Cardiol Rep; 1999 Nov; 1(4):274-81. PubMed ID: 10980854 [TBL] [Abstract][Full Text] [Related]
7. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents]. Scholz H Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988 [TBL] [Abstract][Full Text] [Related]
8. [Prevention of sudden death in myocardial infarct: do experimental results help to understand the clinical reality? The case of the clinical trial SWORD (Survival With ORal D-sotalol)]. Schwartz PJ Cardiologia; 1996 Aug; 41(8):739-45. PubMed ID: 8925528 [No Abstract] [Full Text] [Related]
9. [Class I anti-arrhythmia agents and prevention of sudden death following myocardial infarction]. Boissel JP; Lièvre M; Rosenberg Y Arch Mal Coeur Vaiss; 1991 Feb; 84 Spec No 2():49-54. PubMed ID: 1669239 [TBL] [Abstract][Full Text] [Related]
11. Amiodarone supplants lidocaine in ACLS and CPR protocols. Mizzi A; Tran T; Mangar D; Camporesi EM Anesthesiol Clin; 2011 Sep; 29(3):535-45. PubMed ID: 21871409 [TBL] [Abstract][Full Text] [Related]
12. Management strategies in patients at high risk of sudden cardiac death following myocardial infarction. Sra J; Underwood RD; Akhtar M Indian Heart J; 1995; 47(2):158-62. PubMed ID: 7590846 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs]. Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989 [TBL] [Abstract][Full Text] [Related]
15. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Kamath GS; Mittal S Prog Cardiovasc Dis; 2008; 50(6):439-48. PubMed ID: 18474286 [TBL] [Abstract][Full Text] [Related]
16. Treatment of sudden cardiac death. Current understandings from randomized trials and future research directions. Domanski MJ; Zipes DP; Schron E Circulation; 1997 Jun; 95(12):2694-9. PubMed ID: 9193439 [No Abstract] [Full Text] [Related]
17. A review of the class III antiarrhythmic agents and their uses and implications for patient management. Todd DW J Oral Maxillofac Surg; 2003 Aug; 61(8):928-31. PubMed ID: 12905446 [No Abstract] [Full Text] [Related]
18. A review of carvedilol arrhythmia data in clinical trials. Kowey PR J Cardiovasc Pharmacol Ther; 2005 Jun; 10 Suppl 1():S59-68. PubMed ID: 15965573 [TBL] [Abstract][Full Text] [Related]
19. [Role of antiarrhythmics in the post-infarction period]. Dinanian S Arch Mal Coeur Vaiss; 2000 Apr; 93(3 Spec No):65-9. PubMed ID: 10816803 [TBL] [Abstract][Full Text] [Related]
20. Antiarrhythmic therapy for the prevention of sudden cardiac death. Cairns J; Kerr C; Teo K Can J Cardiol; 2000 Jun; 16 Suppl C():29C-33C. PubMed ID: 10887276 [No Abstract] [Full Text] [Related] [Next] [New Search]